Topline Phase 3 Data: Guselkumab (Tremfya, Janssen Pharmaceuticals) Cools Inflammation and Halts Disease Progression in PsA
Guselkumab (Tremfya, Johnson & Johnson Innovative Medicine) achieved its primary endpoint of reducing signs and symptoms of active psoriatic arthritis (PsA), compared to placebo in the Phase 3b APEX study.